Ospolot 20 mg/ml, Suspension zum Einnehmen

7680698280019 CH-69828 suspension

No image available

Article details

Package size
250
Selling units
250
Measure
ml
Galenic form
suspension
Galenic group
unbekannt

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
18/03/2026
Patient information leaflet
Français
18/03/2026
Patient information leaflet
Italien
18/03/2026

Detailed composition

Substance Quantity Type Category
sultiamum
20.0 MG Substance Wirkstoff (Principe actif)
E 219
2.3 MG Substance HBESI
propylis parahydroxybenzoas natricus
0.6 MG Substance HBESI
sucralosum
- Substance HNIDK
natrii docusas
- Substance HNIDK
xanthani gummi
- Substance HNIDK
natrii dihydrogenophosphas dihydricus
- Substance HNIDK
dikalii phosphas anhydricus
- Substance HNIDK
aromatica
- Substance AROMA
aromatica
- Substance AROMA
E 220
- Substance HBESI
fructosum
- Substance HBESI
glucosum
- Substance HBESI
saccharum
- Substance HBESI
aromatica
- Substance AROMA
acidum phosphoricum concentratum
- Substance HNIDK
aqua purificata
- Substance HNIDK
natrium
0.667 MG Substance HBESI

Reimbursement information

Public price
CHF 121.40
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/02/2026

Authorization holder

Desitin Pharma GmbH

4410 Liestal

Authorization information

Swissmedic authorization number
69828
Drug name
Ospolot, Suspension zum Einnehmen
Galenic form
SUOR
ATC Code
N03AX03
Authorization status
Z
Dispensing category
B
First authorization
05/08/2025
Authorization expiration date
04/08/2030
IT Number
01.07.1.
Domain
Human medicine
Field of application
Antiepileptikum

Package details

Description (FR)
OSPOLOT 20 mg/ml susp 20 mg 250 ml
Description (DE)
OSPOLOT 20 mg/ml Susp 20 mg 250 ml
Market launch
01/02/2026
Narcotic (BTM)
No
Buy us a coffee Explore the data